title: Response to letters regarding article, “Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial”.
authors: Jeff S
authors: JS
authors: Healey
authors: John
authors: J
authors: Eikelboom
authors: Sean
authors: S
authors: Yang
authors: Ellison
authors: E
authors: Themeles
authors: Stuart J
authors: SJ
authors: Connolly
authors: Salim
authors: S
authors: Yusuf
authors: James
authors: J
authors: Douketis
authors: Lars
authors: L
authors: Wallentin
authors: Jonas
authors: J
authors: Oldgren
authors: Hein
authors: H
authors: Heidbuchel
authors: Alvaro
authors: A
authors: Avezum
authors: Paul
authors: P
authors: Reilly
authors: Michael
authors: M
authors: Ezekowitz
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D001562:Benzimidazoles / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008297:Male; D013923:Thromboembolism / Q000188:drug therapy*; D014859:Warfarin / Q000009:adverse effects*; D015091:beta-Alanine / Q000031:analogs & derivatives*
chemical_list: D000925:Anticoagulants; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin